Insight Molecular Diagnostics Inc (IMDX) Stock Price, Quote & News

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 949 409 7600

Website: imdxinc.com

Address:

2 International Plaza Dr., Suite 510, Nashville, United States

Bogwood Feb. 2 at 3:59 PM

$LCTX $STAA $IMDX anyone else surprised at how much light is behind Neal's eyes? Thought he would've had a jaded death stare after dealing with these companies for so long lol

2 · Reply

OfficialStocktwitsUser Jan. 29 at 10:39 AM

$IMDX RSI: 38.48, MACD: 0.1313 Vol: 0.41, MA20: 6.98, MA50: 6.22 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Bogwood Jan. 29 at 3:34 AM

$IMDX I would've expected to see a press release for the clinical trial by now... 👉👈🥺

1 · Reply

SuperGreenToday Jan. 24 at 12:40 PM

$IMDX Share Price: $6.59 Contract Selected: Sep 18, 2026 $7.0 Calls Buy Zone: $1.07 – $1.32 Target Zone: $1.91 – $2.34 Potential Upside: 69% ROI Time to Expiration: 236 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Jan. 24 at 6:00 AM

$IMDX Share Price: $6.59 Contract Selected: Sep 18, 2026 $7.0 Calls Buy Zone: $1.07 – $1.32 Target Zone: $1.86 – $2.28 Potential Upside: 64% ROI Time to Expiration: 237 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Bogwood Jan. 23 at 11:13 PM

$IMDX

0 · Reply

Bogwood Jan. 18 at 9:25 PM

$IMDX Hi guys, nothing heard from IR yet. I can't blame them with all the conferences recently announced, though. Their latest press release highlighted a research paper about decentralized testing, and there was another dPCR competitor mentioned in Werfen/Omixon. What's fascinating is that holoGRAFT uses CNVs and not SNPs, which if you feed into chatgpt the bot swears by SNPs as the better option. Furthermore, there are no FDA trials from Werfen/Omixon about marketing this assay, so I feel more confident that iMDx will win this race 👍🤑👍🧬

0 · Reply

JohnPDaly Jan. 13 at 2:11 PM

IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-13-2026-140452877

0 · Reply

JohnPDaly Jan. 12 at 2:48 PM

$LCTX $IMDX bought more.

0 · Reply

Bogwood Jan. 9 at 6:51 AM

$IMDX Have any of you guys reached out to IR about EU competitors like Devyser or Eurobio/GenDX? They make kitted NGS assays, and Dev has a commercial partner in Thermo Fisher and going through an albeit later FDA trial for ddcf-DNA. If not I will ask for the group

1 · Reply

IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring

Jan 7, 2026, 4:05 PM EST - 27 days ago

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

Jan 6, 2026, 8:00 AM EST - 4 weeks ago

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch

Jan 5, 2026, 7:00 AM EST - 4 weeks ago

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion

Nov 11, 2025, 7:31 AM EST - 3 months ago

Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 3 months ago

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

Nov 3, 2025, 4:05 PM EST - 3 months ago

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week

Oct 13, 2025, 4:05 PM EDT - 4 months ago

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Oct 6, 2025, 7:15 AM EDT - 4 months ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Sep 24, 2025, 7:05 AM EDT - 4 months ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 8, 2025, 7:15 AM EDT - 5 months ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:00 AM EDT - 5 months ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Aug 26, 2025, 4:05 PM EDT - 5 months ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 11, 2025, 4:05 PM EDT - 6 months ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 4, 2025, 4:05 PM EDT - 6 months ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Jul 30, 2025, 4:05 PM EDT - 6 months ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 28, 2025, 4:05 PM EDT - 6 months ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jun 23, 2025, 4:05 PM EDT - 8 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 17, 2025, 7:00 AM EDT - 8 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

May 19, 2025, 4:05 PM EDT - 9 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 12, 2025, 11:32 PM EDT - 9 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 9 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

May 7, 2025, 4:10 PM EDT - 9 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Apr 30, 2025, 8:30 AM EDT - 9 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 29, 2025, 8:30 AM EDT - 10 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Mar 24, 2025, 6:53 PM EDT - 11 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 11 months ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 8, 2025, 8:30 AM EST - 1 year ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 6, 2025, 4:05 PM EST - 1 year ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Nov 12, 2024, 8:52 PM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:45 PM EST - 1 year ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 3 years ago

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 18, 2023, 8:45 AM EDT - 3 years ago

Oncocyte Presents New Data at AACR

Bogwood Feb. 2 at 3:59 PM

$LCTX $STAA $IMDX anyone else surprised at how much light is behind Neal's eyes? Thought he would've had a jaded death stare after dealing with these companies for so long lol

2 · Reply

OfficialStocktwitsUser Jan. 29 at 10:39 AM

0 · Reply

Bogwood Jan. 29 at 3:34 AM

$IMDX I would've expected to see a press release for the clinical trial by now... 👉👈🥺

1 · Reply

SuperGreenToday Jan. 24 at 12:40 PM

0 · Reply

SuperGreenToday Jan. 24 at 6:00 AM

0 · Reply

Bogwood Jan. 23 at 11:13 PM

$IMDX

0 · Reply

Bogwood Jan. 18 at 9:25 PM

0 · Reply

JohnPDaly Jan. 13 at 2:11 PM

0 · Reply

JohnPDaly Jan. 12 at 2:48 PM

$LCTX $IMDX bought more.

0 · Reply

Bogwood Jan. 9 at 6:51 AM

1 · Reply

JohnPDaly Jan. 6 at 1:20 PM

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-06-2026-130348318

1 · Reply

RUNNINWILD Jan. 5 at 3:33 PM

$IMDX they days of cheap shares I’m afraid is going to be coming to an end

1 · Reply

JohnPDaly Jan. 5 at 12:07 PM

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2026/01-05-2026-120057265

0 · Reply

OfficialStocktwitsUser Jan. 2 at 4:38 PM

$IMDX RSI: 69.10, MACD: 0.3052 Vol: 0.78, MA20: 5.65, MA50: 6.10 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

RUNNINWILD Dec. 31 at 12:47 AM

$IMDX i see you.

1 · Reply

SynthesisSage Dec. 26 at 2:10 PM

$IMDX Expectations are recalibrating toward pragmatic delivery instead of lofty projections. Cash efficiency must trend upward while maintaining strategic flexibility. Demonstrated durability would lengthen investor time horizons. The forward path ultimately depends on disciplined delivery.

0 · Reply

JohnPDaly Dec. 24 at 7:48 PM

$IMDX Thanks!

1 · Reply

SuperGreenToday Dec. 22 at 2:17 PM

$IMDX Share Price: $5.41 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.53 – $1.89 Target Zone: $2.68 – $3.28 Potential Upside: 65% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Bogwood Dec. 11 at 6:03 PM

$IMDX Even with all of this year's press releases and events, most still don't see what's going to happen to transplant diagnostics next year and see the situation as not yet "derisked". Do not be deterred by recent price movement fellow holders! The path to $100M top line will light like a tinder box. 80% of the top transplant centers already perform HLA in-house. $NTRA and $CDNA can kiss their biz model goodbye 💋

2 · Reply

RUNNINWILD Dec. 4 at 2:09 AM

$IMDX https://diagnostics.roche.com/global/en/lab-leaders/article/molecular-laboratory-trends.html#:~:text=However%2C%20in%20the%20future%2C%20molecular,drug%20metabolism%20and%20treatment%20response.

0 · Reply

SERaiser Dec. 2 at 3:08 AM

$IMDX Did they submit their FDA Assay?

1 · Reply

RUNNINWILD Dec. 1 at 11:58 PM

$IMDX asked AI why the stock is going down

1 · Reply

Market Cap	186.89M
Revenue (ttm)	1.88M
Net Income (ttm)	-60.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,226.60%
Debt to Equity Ratio	0.00

Volume	7,500
Avg Vol	35,054
Day's Range	N/A - N/A
Shares Out	28.66M
Stochastic %K	70%
Beta	1.11
Analysts	Sell
Price Target	$7.00